Effects of treatment of painful shoulder muscle nodules on shoulder pain, mobility, and muscle function in individuals with shoulder pai

Not Applicable

• Conditions: Shoulder pain; Shoulder Impingement Syndrome; Myofascial Pain Syndrome; Trigger point; C05.550.091.700; C05.550.840; A01.947; C05.651.550

• Registration Number: RBR-3ddg2k
• Lead Sponsor: niversidade Federal do Rio Grande do Norte

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-07-10
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Presence of at least one active or latent PGM, on the symptomatic side, in one of the following muscles: upper trapezius, lower trapezius, supraspinatus, infraspinatus, minor pectoris and middle deltoid.The subjects should have a history of unilateral shoulder pain, lasting more than one week, located in the proximal anterolateral region of the shoulder, or in the C5 or C6 dermatome region; Least three of the special tests for SIS diagnosis considered positive: Neer test; Hawkins' test; Jobe's test; Painful arch test; External rotation resistance test; Gerber test and Speed biceps test.

Exclusion Criteria

Signs and symptoms of bilateral SIS;Primary adhesive capsulitis; Reproduction of shoulder pain which radiates to the entire upper limb; Numbness or tingling in the upper limb or any other symptom in the upper limb during foraminal compression test; History of symptom onset due to glenohumeral displacement or subluxation; Joint deformation in the glenoid or humeral head; Or fracture of the clavicle, scapula or humerus;History of surgical stabilization or repair of the rotator cuff;Groove test or positive seizure test;Signs of complete rupture of the rotator cuff, as evidenced by the positive fall test; Systemic disease involving joints such as rheumatoid arthritis and systemic lupus erythematosus and fibromyalgia, which involves myofascial tissue;Neurological pathologies; Use of analgesics and muscle relaxants 72 hours before the evaluation;Use of corticoid injection 3 months prior to evaluation;Body mass index (BMI)> 28kg /m2;Symptoms of depression, with score 13 in the Beck Depression Inventory;Be there for a period of 1 month without participating in any program of physiotherapeutic treatment, stretching, strengthening or specific resistance exercises for the upper limbs.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expected endpoint: increased pain pressure threshold verified from a digital algometer that exceeds the values of minimum detectable change (MMD) to 95% of each muscle: 0.6 kgf / cm2, upper trapezius; 0.88 kgf / cm 2, lower trapezoid; 1.06kgf / cm2, infraespinal; 0.74 kgf / cm 2, medium deltoid. The values were obtained through training prior to the study to perform the isometric strength evaluation.

Secondary Outcome Measures

Name	Time	Method
Expected: decrease in the number of trigger points (active and latent), evaluated by the manual identification of the second rater.<br>;Expected Outcome: increase in pain-free range of motion, assessed through the digital inclinometer.<br>For minimal detectable change (MDC) at 90%, the following will be considered: minimum clinical change of ADM: 3,4 ° for flexion; 9.29 ° for internal rotation and 16.95 ° for external rotation.<br>The values of MDC were obtained through training training prior to the study to perform the isometric strength assessment.<br> ;Expected outcome: increased isometric force of scapular flexion, external rotation and internal rotation.<br>For the minimum detected change (MDC) at 90%, it will be considered: internal rotation of 21.57; external rotation of 15.54; and scapular flexion of 12.78.<br>The values of MDC were obtained through training training prior to the study to perform the isometric strength assessment.<br>